MRT68921: Dual ULK1/2 Inhibitor for Precision Autophagy Research

Executive Summary: MRT68921 is a highly potent and selective inhibitor of the autophagy-initiating kinases ULK1 and ULK2, with IC50 values of 2.9 nM and 1.1 nM respectively, effectively blocking ATG13 phosphorylation and autophagic flux in wild-type but not mutant ULK1 (M92T) cells (APExBIO). It demonstrates over 80% inhibition of TBK1/IKK and several AMPK-related kinases in vitro, though evidence from LKB1 knockout MEFs suggests its primary autophagy target is ULK1/2 (Phadwal et al., 2025). MRT68921 is insoluble in water and ethanol but dissolves in DMSO at ≥2.18 mg/mL with gentle warming. It is supplied as a hydrochloride salt and is strictly for preclinical research use. No in vivo or clinical trial data currently support its use. Its utility lies in dissecting autophagy pathways, specifically for ATG13 and LC3-based assays.

Biological Rationale

Autophagy is an evolutionarily conserved catabolic process responsible for degrading damaged organelles, misfolded proteins, and intracellular pathogens in eukaryotic cells (Phadwal et al., 2025). This process is essential for maintaining cellular homeostasis and adaptation to metabolic stress. The core autophagy machinery is orchestrated by serine/threonine protein kinases, most notably ULK1 and ULK2, which initiate autophagosome formation in response to nutrient deprivation and mTORC1 inhibition. Autophagy not only regulates protein and organelle turnover but also modulates lipid droplet metabolism, mitigating lipotoxicity induced by excess lipid accumulation. In multiple cell types, inhibition of autophagy impairs LC3 lipidation and ATG13 phosphorylation, resulting in defective clearance of cytoplasmic material and increased susceptibility to metabolic stress and disease (Phadwal et al., 2025).

Mechanism of Action of MRT68921

MRT68921 is a synthetic small-molecule inhibitor that targets the ATP-binding pocket of ULK1 and ULK2 kinases, with nanomolar potency (IC50 for ULK1: 2.9 nM; ULK2: 1.1 nM; DMSO, kinase buffer, 25°C) (APExBIO). By competitively inhibiting ULK1/2 activity, MRT68921 prevents phosphorylation of ATG13, a key event required for autophagosome initiation. This blockade is confirmed by the absence of ATG13 phosphorylation and LC3 flux in wild-type cells treated with MRT68921, while cells expressing the kinase-impaired ULK1 (M92T) mutant are resistant to inhibition. Although MRT68921 exhibits >80% inhibition against TBK1, IKK, and several AMPK-related kinases in vitro, functional studies in LKB1-deficient mouse embryonic fibroblasts (MEFs) indicate that these off-targets do not contribute significantly to autophagy modulation by MRT68921 (Phadwal et al., 2025). This selectivity enables targeted interrogation of the mTOR-ULK1/2-autophagy axis in cellular models.

Evidence & Benchmarks

• MRT68921 blocks ATG13 phosphorylation and LC3 flux in wild-type, but not ULK1 (M92T) mutant cells, confirming its specificity for ULK1/2 (Phadwal et al., 2025).
• Demonstrates >80% inhibition of TBK1/IKK and AMPK-related kinases in biochemical assays, but these are not primary targets in autophagy inhibition according to LKB1 knockout MEFs (APExBIO).
• Potency: IC50 for ULK1 = 2.9 nM; IC50 for ULK2 = 1.1 nM (kinase assay, 25°C, kinase buffer, DMSO solvent) (APExBIO).
• MRT68921 is insoluble in water and ethanol but dissolves at ≥2.18 mg/mL in DMSO with gentle warming and sonication (APExBIO).
• No published in vivo or clinical trial data currently support its use in animal or human studies (APExBIO).
• Autophagy inhibition by MRT68921 impairs lipid droplet turnover and may increase cellular susceptibility to lipotoxicity if used in models of metabolic stress (Phadwal et al., 2025).

This article updates and extends coverage found in MRT68921 (SKU B6174): Dual ULK1/2 Inhibition for Reliable Research by providing detailed mechanistic evidence and solubility parameters not previously elaborated. For a technical comparison with energy stress and AMPK signaling, see Advanced Strategies for Precise Autophagy Inhibition, which this article extends by clarifying selectivity and off-target effects.

Applications, Limits & Misconceptions

MRT68921 is optimized for preclinical research applications requiring robust and selective inhibition of the autophagy initiation complex. It is particularly valuable in assays measuring ATG13 phosphorylation and LC3 flux, standard readouts for autophagy blockade. Use of MRT68921 enables precise dissection of the mTOR-ULK1/2 axis, facilitating studies on cell viability, proliferation, and lipid metabolism. However, its utility is limited by lack of in vivo and clinical data, potential off-target effects on TBK1/IKK and AMPK-related kinases (at high concentrations), and solubility constraints.

Common Pitfalls or Misconceptions

• MRT68921 is NOT suitable for in vivo or clinical use. No animal or human pharmacokinetic or safety data are available.
• It does NOT inhibit autophagy in cells expressing kinase-impaired ULK1 (M92T mutant). Specificity is lost if the target is absent or mutated.
• Solubility is limited to DMSO; do not attempt to dissolve in water or ethanol.
• Off-target kinase inhibition may occur at high concentrations, especially for TBK1/IKK and AMPK-related kinases.
• It does NOT directly modulate mTORC1 activity; its effect is upstream via ULK1/2 inhibition.

Workflow Integration & Parameters

MRT68921 is supplied as a hydrochloride salt (molecular weight 434.58; formula C25H34N6O·xHCl) and should be stored at -20°C (APExBIO). For in vitro experiments, stock solutions should be prepared in DMSO at concentrations ≥2.18 mg/mL using gentle warming and sonication to ensure complete dissolution. Typical working concentrations for cell-based assays range from 10 nM to 1 μM, depending on assay sensitivity and cell type. Autophagy inhibition can be monitored via immunoblot for ATG13 phosphorylation, LC3-I/II conversion, or fluorescence-based LC3 flux reporters. Proper controls include DMSO vehicle, rapamycin-induced autophagy (as in Phadwal et al., 2025), and mutant ULK1 cell lines. For a scenario-driven laboratory perspective, see MRT68921 (SKU B6174): Dual ULK1/2 Inhibition, which this article augments by specifying storage and preparation protocols.

Conclusion & Outlook

MRT68921, as provided by APExBIO, is a best-in-class dual ULK1/2 inhibitor that empowers researchers to dissect autophagy signaling with high selectivity and reproducibility. Its well-characterized mechanism, potency, and defined solubility make it the preferred tool for preclinical autophagy research targeting the mTOR-ULK1/2 axis. While its application is currently limited to in vitro studies, future research may clarify its translational potential. For further technical optimization and advanced protocol development, see MRT68921: Dual ULK1/2 Inhibitor for Precision Autophagy Research, which this article extends by emphasizing boundary conditions and selectivity profiles.